Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 3 | 2018 | 124 | 1.170 |
Why?
|
| Breast Neoplasms | 17 | 2024 | 16244 | 0.770 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 93 | 0.590 |
Why?
|
| Scalp | 1 | 2017 | 155 | 0.510 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 177 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 16612 | 0.400 |
Why?
|
| Quinolines | 4 | 2024 | 403 | 0.390 |
Why?
|
| RANK Ligand | 1 | 2012 | 116 | 0.380 |
Why?
|
| Plasmacytoma | 1 | 2011 | 123 | 0.360 |
Why?
|
| Receptor, ErbB-2 | 6 | 2024 | 2649 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 1381 | 0.300 |
Why?
|
| Quality of Life | 3 | 2018 | 4755 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 1237 | 0.260 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 695 | 0.260 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 531 | 0.190 |
Why?
|
| Proteogenomics | 1 | 2022 | 109 | 0.190 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1065 | 0.190 |
Why?
|
| Estrogen Antagonists | 1 | 2022 | 219 | 0.190 |
Why?
|
| Adenomyoepithelioma | 1 | 2019 | 9 | 0.170 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 4994 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 2287 | 0.170 |
Why?
|
| Cholecalciferol | 1 | 2019 | 51 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2669 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 4496 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 443 | 0.160 |
Why?
|
| Arthralgia | 1 | 2019 | 97 | 0.160 |
Why?
|
| Hair Diseases | 1 | 2018 | 42 | 0.150 |
Why?
|
| Cryotherapy | 1 | 2018 | 67 | 0.150 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2018 | 46 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14653 | 0.150 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 82 | 0.140 |
Why?
|
| Female | 22 | 2024 | 149288 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 227 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 314 | 0.140 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 180 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2017 | 243 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2017 | 339 | 0.120 |
Why?
|
| Humans | 26 | 2024 | 272087 | 0.120 |
Why?
|
| Neoplasms | 2 | 2018 | 15930 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 909 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 848 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 754 | 0.110 |
Why?
|
| Taxoids | 1 | 2017 | 1010 | 0.110 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 33 | 0.100 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 26 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2011 | 835 | 0.100 |
Why?
|
| Intussusception | 1 | 2012 | 53 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 65 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 72 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2015 | 2099 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2018 | 1860 | 0.090 |
Why?
|
| Aged | 9 | 2024 | 73517 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 640 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2015 | 586 | 0.090 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 10750 | 0.090 |
Why?
|
| Middle Aged | 12 | 2024 | 90460 | 0.080 |
Why?
|
| Risk Factors | 3 | 2021 | 18051 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1324 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2021 | 6885 | 0.080 |
Why?
|
| Trastuzumab | 2 | 2023 | 736 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 698 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 5213 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 3395 | 0.070 |
Why?
|
| Adult | 8 | 2024 | 81933 | 0.070 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 183 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 1284 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 2270 | 0.060 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 1047 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 304 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2011 | 2446 | 0.060 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 64 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 384 | 0.050 |
Why?
|
| Breast | 2 | 2019 | 1380 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 114 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2023 | 33909 | 0.050 |
Why?
|
| Apoptosis | 3 | 2018 | 7837 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 160 | 0.050 |
Why?
|
| Oxazepines | 1 | 2019 | 3 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 1105 | 0.040 |
Why?
|
| Carboplatin | 1 | 2022 | 879 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1615 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 106 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 109 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 8 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 20 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 953 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 42 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 390 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 62 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 946 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 304 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5330 | 0.040 |
Why?
|
| Prognosis | 3 | 2022 | 22555 | 0.030 |
Why?
|
| Survival Rate | 2 | 2019 | 12534 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 2624 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1622 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7792 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 1437 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 560 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 63 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 945 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 520 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1882 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 524 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 448 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 13993 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 430 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Glioma | 1 | 2005 | 1988 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 267 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3543 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2867 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 31066 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2621 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2268 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 62822 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 2054 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3980 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 6911 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5115 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4071 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2400 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4400 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3544 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4195 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9500 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 4257 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5187 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2018 | 12223 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 143 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 3546 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 211 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4963 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 15279 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 4968 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 621 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1832 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 22142 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 2085 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 36053 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 14881 | 0.010 |
Why?
|
| Male | 1 | 2008 | 129088 | 0.000 |
Why?
|